Anthera Pharmaceuticals (ANTH) 4.79 $ANTH
The Zacks Analyst Blog Highlights: Gilead Sciences, Biogen, Geron, Johnson & Johnson and Anthera Pharmaceuticals - Press Releases
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 8:30AM CDT
The Zacks Analyst Blog Highlights: Gilead Sciences, Biogen, Geron, Johnson & Johnson and Anthera Pharmaceuticals
JNJ: 100.43 (+0.13), BIIB: 423.57 (+1.46), GILD: 104.18 (-1.02), ANTH: 4.79 (+0.10), GERN: 4.20 (-0.04)
Forget Gilead (GILD), Buy These Impressive Biotech Stocks Instead - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 8:09AM CDT
It's time we overlooked Gilead for some biotech growth stocks.
BIIB: 423.57 (+1.46), JNJ: 100.43 (+0.13), ESRX: 86.12 (+0.02), PCYC: 256.98 (-0.77), GILD: 104.18 (-1.02), ANTH: 4.79 (+0.10), GERN: 4.20 (-0.04), ABBV: 64.52 (+0.91)
Play UnitedHealth Q1 Strength With This Health Care ETF
Zacks Funds - Seeking Alpha - Fri Apr 17, 9:30AM CDT
The largest U.S. health insurer UnitedHealth Group (NYSE: UNH ) reported blockbuster first-quarter 2015 results. It topped our estimates on both the top and the bottom lines as well as raised its full-year outlook. UnitedHealth Q1 Results in Focus ...
CI: 130.25 (-0.45), IHF: 134.01 (-0.23), ANTH: 4.79 (+0.10), UNH: 117.81 (-1.47), AET: 107.95 (-0.41), HUM: 180.01 (-0.12)
3 Biotech Stocks Under $10 with Amazing Growth Prospects - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 15, 9:52AM CDT
The biotech sector is witnessing changing dynamics with the focus shifting from large caps to smaller companies with high growth potential.
JNJ: 100.43 (+0.13), ESRX: 86.12 (+0.02), PCYC: 256.98 (-0.77), GILD: 104.18 (-1.02), ANTH: 4.79 (+0.10), CYTX: 0.96 (-0.09), GERN: 4.20 (-0.04), PFE: 34.93 (+0.04), AMGN: 169.10 (+0.64), ABBV: 64.52 (+0.91), HSP: 87.80 (+0.04), NVS: 103.45 (-0.62)
Updates on Biotech Stocks -- Gilead Sciences, Arena Pharma, ACADIA Pharma, Halozyme Therapeutics, and Anthera Pharma
PR Newswire - Tue Apr 14, 7:40AM CDT
Editor Note: For more information about this release, please scroll to bottom.
ACAD: 38.55 (-0.20), HALO: 16.03 (+0.15), GILD: 104.18 (-1.02), ANTH: 4.79 (+0.10), ARNA: 4.47 (+0.01)
PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022
M2 - Thu Apr 09, 1:36AM CDT
Summary
ANTH: 4.79 (+0.10), LLY: 72.30 (+0.09)
The Top-Performing Biotech Stock During a Sizzling First Quarter
at The Street - Wed Apr 01, 8:30AM CDT
That was one crazy first quarter for the biotech sector. Here's where biotech stocks stand on April Fool's Day.
CRMD: 8.86 (-0.28), BIIB: 423.57 (+1.46), ESPR: 100.53 (-2.60), FMI: 48.71 (-0.96), ANTH: 4.79 (+0.10), XBI: 232.63 (-0.32), IBB: 363.84 (-0.66), TRIL: 20.67 (-2.53)
Nephropathy Global Clinical Trials Review, H1, 2015
M2 - Tue Mar 31, 4:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g9gmj6/nephropathy) has announced the addition of the "Nephropathy Global Clinical Trials Review, H1, 2015" report to their offering. Nephropathy Global Clinical Trials Review, H1, 2015" provides data on the Nephropathy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Nephropathy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Nephropathy. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Nephropathy Therapeutics Clinical Trials - Pfizer Inc. - Novartis AG - Mallinckrodt plc - Rigel Pharmaceuticals, Inc. - Kliniken der Stadt Koln gGmbH - AstraZeneca PLC - Astellas Pharma Inc. - Anthera Pharmaceuticals Inc. - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/g9...ephropathy
ANTH: 4.79 (+0.10), PFE: 34.93 (+0.04), AZN: 73.35 (+0.65), ABBV: 64.52 (+0.91), RIGL: 4.24 (+0.07), NVS: 103.45 (-0.62)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 4:38PM CDT
ANTH: 4.79 (+0.10), FRED: 16.84 (-0.14), NM: 3.91 (-0.02), SCMP: 21.75 (+0.47), SALT: 2.20 (+0.10), IPI: 11.86 (-0.02), TTI: 7.15 (-0.02), FIVE: 35.27 (-0.01), GSAT: 3.14 (-0.06), WTW: 7.81 (+0.16)
Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
PR Newswire - Mon Mar 23, 3:05PM CDT
Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), today announced that it has completed the previously announced underwritten public offering of 5,555,556 shares of its common stock, offered at a price of $4.50 per share. In addition, Anthera has granted the underwriters a 30-day option to purchase up to an additional 833,333 shares of common stock to cover over-allotments, if any. The gross proceeds to the Company from the sale of shares in this offering, before deducting customary underwriting discounts and commissions, were approximately $25,000,000 million. Anthera intends to use the net proceeds from this offering for clinical research and development and general corporate purposes.
ANTH: 4.79 (+0.10)
Anthera Announces $3 Million Research Award from Cystic Fibrosis Foundation Therapeutics for Development of Sollpura - a Novel Enzyme Therapy
PR Newswire - Thu Mar 19, 2:00PM CDT
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) today announced it has received an award from Cystic Fibrosis Foundation Therapeutics Inc. of up to $3 million to support the manufacturing and clinical development of Anthera's novel pancreatic enzyme replacement therapy, Sollpura(TM) (liprotamase). Cystic Fibrosis Foundation Therapeutics is a non-profit affiliate of the Cystic Fibrosis Foundation.
ANTH: 4.79 (+0.10)
Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
PR Newswire - Wed Mar 18, 8:01AM CDT
Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced the pricing of an underwritten public offering of 5,555,556 shares of its common stock, offered at a price of $4.50 per share. The Company estimates that the gross proceeds from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Anthera, will be $25 million. The offering is expected to close on or about March 23, 2015, subject to customary closing conditions. In addition, Anthera has granted the underwriter a 30-day option to purchase up to an additional 833,333 shares of common stock to cover over-allotments, if any. The Company intends to use the net proceeds from the offering for clinical research and development and general corporate purposes.
ANTH: 4.79 (+0.10)
Anthera Pharmaceuticals to issue common stock in public offering
M2 - Wed Mar 18, 5:39AM CDT
Biopharmaceutical company Anthera Pharmaceuticals (NasdaqGM:ANTH) revealed on Tuesday that it plans to offer and sell shares of its common stock in a public offering.
ANTH: 4.79 (+0.10)
Anthera Pharma initiates equity offering
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 4:05PM CDT
ANTH: 4.79 (+0.10)
Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
PR Newswire - Tue Mar 17, 3:06PM CDT
Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering to cover over-allotments, if any. The Company intends to use the net proceeds from the offering for clinical research and development and general corporate purposes. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
ANTH: 4.79 (+0.10)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 11:45AM CDT
VEC: 26.06 (-0.26), RADA: 2.64 (-0.06), BSPM: 1.45 (-0.05), AMRN: 2.34 (-0.05), BBX: 18.94 (unch), WGBS: 4.66 (-0.08), EGY: 2.29 (-0.07), AVID: 16.35 (+0.29), FVE: 4.48 (-0.03), ATNM: 3.01 (-0.07), ESPR: 100.53 (-2.60), CALL: 6.78 (-0.15), BDE: 9.35 (-0.15), ANTH: 4.79 (+0.10), ARTX: 2.98 (-0.10), STEM: 0.82 (-0.06), MTL: 1.29 (-0.01), HELI: 1.12 (-0.02), NVFY: 2.61 (+0.22), DSCO: 1.25 (unch)
Premarket Gainers / Losers as of 9:15 am
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 8:19AM CDT
SD: 1.86 (-0.06), SSH: 4.18 (+0.04), PLUG: 2.65 (-0.02), BBX: 18.94 (unch), IMNP: 1.94 (-0.06), MGM: 22.03 (+0.32), DSW: 36.68 (+0.08), VEEV: 27.12 (+0.28), ESPR: 100.53 (-2.60), CYTX: 0.96 (-0.09), BDE: 9.35 (-0.15), ARTX: 2.98 (-0.10), ANTH: 4.79 (+0.10), WYY: 1.54 (+0.08), CJJD: 3.97 (+0.46), DSCO: 1.25 (unch)
Anthera reports 4Q loss
Automated Insights - Mon Mar 16, 8:54AM CDT
HAYWARD, Calif. (AP) _ Anthera Pharmaceuticals Inc. (ANTH) on Monday reported a loss of $7.4 million in its fourth quarter.
ANTH: 4.79 (+0.10)
The Zacks Analyst Blog Highlights: Gilead Sciences, Biogen, Geron, Johnson & Johnson and Anthera Pharmaceuticals - Press Releases
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 8:30AM CDT
The Zacks Analyst Blog Highlights: Gilead Sciences, Biogen, Geron, Johnson & Johnson and Anthera Pharmaceuticals
JNJ: 100.43 (+0.13), BIIB: 423.57 (+1.46), GILD: 104.18 (-1.02), ANTH: 4.79 (+0.10), GERN: 4.20 (-0.04)
Forget Gilead (GILD), Buy These Impressive Biotech Stocks Instead - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 8:09AM CDT
It's time we overlooked Gilead for some biotech growth stocks.
BIIB: 423.57 (+1.46), JNJ: 100.43 (+0.13), ESRX: 86.12 (+0.02), PCYC: 256.98 (-0.77), GILD: 104.18 (-1.02), ANTH: 4.79 (+0.10), GERN: 4.20 (-0.04), ABBV: 64.52 (+0.91)
Play UnitedHealth Q1 Strength With This Health Care ETF
Zacks Funds - Seeking Alpha - Fri Apr 17, 9:30AM CDT
The largest U.S. health insurer UnitedHealth Group (NYSE: UNH ) reported blockbuster first-quarter 2015 results. It topped our estimates on both the top and the bottom lines as well as raised its full-year outlook. UnitedHealth Q1 Results in Focus ...
CI: 130.25 (-0.45), IHF: 134.01 (-0.23), ANTH: 4.79 (+0.10), UNH: 117.81 (-1.47), AET: 107.95 (-0.41), HUM: 180.01 (-0.12)
3 Biotech Stocks Under $10 with Amazing Growth Prospects - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 15, 9:52AM CDT
The biotech sector is witnessing changing dynamics with the focus shifting from large caps to smaller companies with high growth potential.
JNJ: 100.43 (+0.13), ESRX: 86.12 (+0.02), PCYC: 256.98 (-0.77), GILD: 104.18 (-1.02), ANTH: 4.79 (+0.10), CYTX: 0.96 (-0.09), GERN: 4.20 (-0.04), PFE: 34.93 (+0.04), AMGN: 169.10 (+0.64), ABBV: 64.52 (+0.91), HSP: 87.80 (+0.04), NVS: 103.45 (-0.62)
Updates on Biotech Stocks -- Gilead Sciences, Arena Pharma, ACADIA Pharma, Halozyme Therapeutics, and Anthera Pharma
PR Newswire - Tue Apr 14, 7:40AM CDT
Editor Note: For more information about this release, please scroll to bottom.
ACAD: 38.55 (-0.20), HALO: 16.03 (+0.15), GILD: 104.18 (-1.02), ANTH: 4.79 (+0.10), ARNA: 4.47 (+0.01)
PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022
M2 - Thu Apr 09, 1:36AM CDT
Summary
ANTH: 4.79 (+0.10), LLY: 72.30 (+0.09)
The Top-Performing Biotech Stock During a Sizzling First Quarter
at The Street - Wed Apr 01, 8:30AM CDT
That was one crazy first quarter for the biotech sector. Here's where biotech stocks stand on April Fool's Day.
CRMD: 8.86 (-0.28), BIIB: 423.57 (+1.46), ESPR: 100.53 (-2.60), FMI: 48.71 (-0.96), ANTH: 4.79 (+0.10), XBI: 232.63 (-0.32), IBB: 363.84 (-0.66), TRIL: 20.67 (-2.53)
Nephropathy Global Clinical Trials Review, H1, 2015
M2 - Tue Mar 31, 4:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g9gmj6/nephropathy) has announced the addition of the "Nephropathy Global Clinical Trials Review, H1, 2015" report to their offering. Nephropathy Global Clinical Trials Review, H1, 2015" provides data on the Nephropathy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Nephropathy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Nephropathy. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Nephropathy Therapeutics Clinical Trials - Pfizer Inc. - Novartis AG - Mallinckrodt plc - Rigel Pharmaceuticals, Inc. - Kliniken der Stadt Koln gGmbH - AstraZeneca PLC - Astellas Pharma Inc. - Anthera Pharmaceuticals Inc. - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/g9...ephropathy
ANTH: 4.79 (+0.10), PFE: 34.93 (+0.04), AZN: 73.35 (+0.65), ABBV: 64.52 (+0.91), RIGL: 4.24 (+0.07), NVS: 103.45 (-0.62)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 4:38PM CDT
ANTH: 4.79 (+0.10), FRED: 16.84 (-0.14), NM: 3.91 (-0.02), SCMP: 21.75 (+0.47), SALT: 2.20 (+0.10), IPI: 11.86 (-0.02), TTI: 7.15 (-0.02), FIVE: 35.27 (-0.01), GSAT: 3.14 (-0.06), WTW: 7.81 (+0.16)
Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
PR Newswire - Mon Mar 23, 3:05PM CDT
Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), today announced that it has completed the previously announced underwritten public offering of 5,555,556 shares of its common stock, offered at a price of $4.50 per share. In addition, Anthera has granted the underwriters a 30-day option to purchase up to an additional 833,333 shares of common stock to cover over-allotments, if any. The gross proceeds to the Company from the sale of shares in this offering, before deducting customary underwriting discounts and commissions, were approximately $25,000,000 million. Anthera intends to use the net proceeds from this offering for clinical research and development and general corporate purposes.
ANTH: 4.79 (+0.10)
Anthera Announces $3 Million Research Award from Cystic Fibrosis Foundation Therapeutics for Development of Sollpura - a Novel Enzyme Therapy
PR Newswire - Thu Mar 19, 2:00PM CDT
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) today announced it has received an award from Cystic Fibrosis Foundation Therapeutics Inc. of up to $3 million to support the manufacturing and clinical development of Anthera's novel pancreatic enzyme replacement therapy, Sollpura(TM) (liprotamase). Cystic Fibrosis Foundation Therapeutics is a non-profit affiliate of the Cystic Fibrosis Foundation.
ANTH: 4.79 (+0.10)
Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
PR Newswire - Wed Mar 18, 8:01AM CDT
Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced the pricing of an underwritten public offering of 5,555,556 shares of its common stock, offered at a price of $4.50 per share. The Company estimates that the gross proceeds from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Anthera, will be $25 million. The offering is expected to close on or about March 23, 2015, subject to customary closing conditions. In addition, Anthera has granted the underwriter a 30-day option to purchase up to an additional 833,333 shares of common stock to cover over-allotments, if any. The Company intends to use the net proceeds from the offering for clinical research and development and general corporate purposes.
ANTH: 4.79 (+0.10)
Anthera Pharmaceuticals to issue common stock in public offering
M2 - Wed Mar 18, 5:39AM CDT
Biopharmaceutical company Anthera Pharmaceuticals (NasdaqGM:ANTH) revealed on Tuesday that it plans to offer and sell shares of its common stock in a public offering.
ANTH: 4.79 (+0.10)
Anthera Pharma initiates equity offering
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 4:05PM CDT
ANTH: 4.79 (+0.10)
Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
PR Newswire - Tue Mar 17, 3:06PM CDT
Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering to cover over-allotments, if any. The Company intends to use the net proceeds from the offering for clinical research and development and general corporate purposes. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
ANTH: 4.79 (+0.10)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 11:45AM CDT
VEC: 26.06 (-0.26), RADA: 2.64 (-0.06), BSPM: 1.45 (-0.05), AMRN: 2.34 (-0.05), BBX: 18.94 (unch), WGBS: 4.66 (-0.08), EGY: 2.29 (-0.07), AVID: 16.35 (+0.29), FVE: 4.48 (-0.03), ATNM: 3.01 (-0.07), ESPR: 100.53 (-2.60), CALL: 6.78 (-0.15), BDE: 9.35 (-0.15), ANTH: 4.79 (+0.10), ARTX: 2.98 (-0.10), STEM: 0.82 (-0.06), MTL: 1.29 (-0.01), HELI: 1.12 (-0.02), NVFY: 2.61 (+0.22), DSCO: 1.25 (unch)
Premarket Gainers / Losers as of 9:15 am
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 8:19AM CDT
SD: 1.86 (-0.06), SSH: 4.18 (+0.04), PLUG: 2.65 (-0.02), BBX: 18.94 (unch), IMNP: 1.94 (-0.06), MGM: 22.03 (+0.32), DSW: 36.68 (+0.08), VEEV: 27.12 (+0.28), ESPR: 100.53 (-2.60), CYTX: 0.96 (-0.09), BDE: 9.35 (-0.15), ARTX: 2.98 (-0.10), ANTH: 4.79 (+0.10), WYY: 1.54 (+0.08), CJJD: 3.97 (+0.46), DSCO: 1.25 (unch)
Anthera reports 4Q loss
Automated Insights - Mon Mar 16, 8:54AM CDT
HAYWARD, Calif. (AP) _ Anthera Pharmaceuticals Inc. (ANTH) on Monday reported a loss of $7.4 million in its fourth quarter.
ANTH: 4.79 (+0.10)
